Market Minds Advisory
Dementia Management Market

Dementia Management Market: Anti-Amyloid Therapeutics and the Disease-Modifying Transition

Rising global dementia prevalence and newly approved anti-amyloid therapeutics are pushing health systems toward disease-modifying treatment pathways, forcing legacy symptomatic drug makers to rebuild pipelines around biomarker-confirmed early intervention quickly.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$9.2BMarket Size 2025
2036 FORECAST VALUE$24.7BBase Case , 2026 to 2036
CAGR 2026 TO 20369.4 %Bull 10.6% / Bear 8.1%
INCREMENTAL OPPORTUNITY$14.7BNet 10- year value creation
EXPANSION MULTIPLE2.46x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Dementia management procurement has shifted from a purely symptomatic prescribing decision to a biomarker-confirmed treatment pathway, as neurologists increasingly evaluate anti-amyloid eligibility and diagnostic confirmation capability alongside drug cost when selecting a primary treatment protocol across every affiliated memory care service line.
Anti-amyloid disease-modifying therapeutics are growing at roughly 1.86x the market average as health systems expand biomarker testing infrastructure to identify eligible early-stage patients. North America retains the largest revenue base on dense specialty neurology infrastructure and established reimbursement pathways, while South Asia is compounding fastest as India's expanding aging population and healthcare infrastructure pull demand into the category at an accelerating pace nationwide.
Competitive intensity concentrates among five diversified pharmaceutical manufacturers that increasingly bundle anti-amyloid therapeutics, diagnostic biomarker testing, and care management support into a single treatment pathway contract, leaving smaller regional producers to compete on price for standard uncertified symptomatic formats. Diagnostic confirmation depth and treatment outcomes data, not drug pricing alone, increasingly determine which suppliers win multi-year health system contracts. Group purchasing organizations are beginning to standardize dementia treatment protocol selection across affiliated memory care networks.
Market Definition
The dementia management market covers therapeutics, diagnostic testing, and care management services used to treat and manage Alzheimer's disease and related dementias, spanning anti-amyloid disease-modifying drugs, cholinesterase inhibitors and memantine, diagnostic imaging and biomarker testing, behavioral symptom management products, and institutional and home-based care management services. General neurological disorder treatments not specific to dementia are excluded from market scope.
Base Year Value
$9.2B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
9.4% base case. Bull 10.6%. Bear 8.1%.
Fastest Growth Segment
Anti-Amyloid Disease-Modifying Therapeutics: 17.5% CAGR
Fastest Growth Country
China: 15.2% CAGR
Fastest Growth Region
South Asia and Pacific: 11.4% CAGR
Largest Region
North America: 32% of 2025 global value
Market Leaders
Eisai Co Ltd, Biogen Inc, Eli Lilly and Company, Novartis AG, Otsuka Holdings Co Ltd. Source: MMA Analysis based on company annual reports.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Dementia Management Market Forecast Scenarios

dementia-management-market-size-forecast-scenario-1787305346369
Between 2020 and 2025 the market grew at an estimated 7.9% historical CAGR, accelerating as anti-amyloid therapeutics gained regulatory approval and biomarker diagnostic infrastructure expanded across major developed markets throughout the historical period, while health systems steadily built early detection pathways nationwide and across affiliated memory care networks. Manufacturers investing early in biomarker diagnostic partnerships captured disproportionate share of this accelerating demand.
The base case assumes 9.4% CAGR through 2036, anchored in three mechanisms: rising global dementia prevalence across major developed and emerging markets requiring proportional treatment and care management capacity, expanding biomarker diagnostic infrastructure sustaining base demand for early-stage disease-modifying intervention, and growing regulatory approval of anti-amyloid therapeutics pushing health systems toward higher specification treatment pathways. Digital cognitive monitoring adoption adds a reinforcing tailwind as remote assessment tools expand early detection reach.
A bull scenario, near 10.6% CAGR, assumes faster anti-amyloid adoption and accelerated biomarker diagnostic expansion pull premium treatment orders forward across more health systems. The bear case, near 8.1% CAGR, assumes broader healthcare capital spending moderates amid economic pressure and health systems extend existing symptomatic treatment protocols rather than building disease-modifying treatment infrastructure on the standard adoption cycle.

Anti-Amyloid Approval Reshapes Dementia Treatment Pathways

Three forces are converging on dementia management demand simultaneously: rising global dementia prevalence requiring proportional treatment and care management capacity, expanding biomarker diagnostic infrastructure sustaining base demand for early-stage intervention, and growing regulatory approval of anti-amyloid therapeutics pushing health systems toward higher specification treatment pathways. Neurologists that once treated dementia as a purely symptomatic management condition now specify b
MARKET CONCENTRATION52%Combined revenue share held by top five pharmaceutical manufacturers
ANTI-AMYLOID TREATMENT ASP$26,500Blended average annual treatment cost for anti-amyloid therapy
BIOMARKER TESTING PENETRATION24%Share of diagnosed patients receiving confirmatory biomarker testing
TOP PRODUCING COUNTRYUnited StatesLeading country for installed dementia therapeutic manufacturing capacity
EARLY-STAGE DIAGNOSIS RATE31%Share of dementia cases diagnosed at an early treatable stage
AVERAGE TREATMENT COURSE LENGTH18-24 moTypical duration of anti-amyloid disease-modifying treatment course today
Commercially, the category increasingly resembles a treatment pathway partnership bundled around diagnostic confirmation support and infusion care coordination rather than a transactional prescription sale. Health systems and manufacturers commit to multi-year supply and protocol agreements spanning therapeutic manufacturing, biomarker testing partnerships, and infusion site training, since fragmenting these functions across multiple vendors creates treatment coordination gaps that a unified relationship avoids across the care pathway.
Over the next decade, expect anti-amyloid disease-modifying therapeutics to keep gaining share within the broader dementia management budget as clinical evidence accumulates and biomarker testing costs decline, continued consolidation among smaller regional pharmaceutical manufacturers unable to fund disease-modifying development, and growing scrutiny of treatment outcomes driving faster protocol adoption cycles across major health systems worldwide, particularly among specialty memory care networks.
"Families used to accept a dementia diagnosis as something you managed rather than treated. Now neurologists are building entire referral pathways around biomarker confirmation, because catching amyloid pathology early enough to qualify for disease-modifying therapy has become the whole clinical strategy."
Director, Neurology and Cognitive Health Practice · MMA Alzheimer's and Dementia

Market Trends

Health Systems Build Biomarker Diagnostic Pathways

Health systems and specialty memory care networks are increasingly building dedicated biomarker diagnostic pathways to identify anti-amyloid treatment-eligible patients, replacing what were historically purely clinical symptom-based diagnostic protocols built around cognitive testing alone across most memory care evaluations. Each new biomarker pathway commitment increasingly requires manufacturers to demonstrate diagnostic partnership reliability alongside existing therapeutic capabilities, a compliance bar that has tightened considerably over the past several years across the industry. Manufacturers completing successful diagnostic partnership integration report meaningfully improved health system contract retention, reinforcing biomarker confirmation as the standard specification for new dementia treatment investment nationwide.
Market Impact: Adds 12 million diagnosed cases

Digital Cognitive Monitoring Expands Early Detection Reach

Primary care networks and telehealth platforms are increasingly deploying digital cognitive assessment and monitoring tools to expand early dementia detection beyond specialty neurology settings, replacing what were historically limited in-person cognitive testing protocols built around specialist availability alone across most primary care screening visits. Each new digital monitoring commitment increasingly requires manufacturers to demonstrate validated screening accuracy alongside existing platform capabilities, a service expectation that has tightened considerably over the past several years. Manufacturers completing expanded validation studies report meaningfully improved primary care adoption, reinforcing digital cognitive monitoring as the standard specification for new early detection investment across every major primary care network.
Market Impact: Adds 16% to biomarker testing volum

Market Opportunities and Growth Drivers

Rising Global Dementia Prevalence Drives Base Demand

Expanding aging population cohorts across major developed and emerging markets continue driving surging dementia case volume, proportionally expanding requirements for both diagnostic capacity and treatment infrastructure capable of managing an increasingly large patient population across primary care and specialty settings. Manufacturers report that health systems increasingly require dedicated early-stage diagnostic and treatment pathways validated specifically for biomarker-confirmed patient populations rather than relying on symptomatic management protocols alone. This prevalence growth is expanding the addressable dementia management market well beyond the traditional late-stage care categories that historically drove most category demand across the broader neurology supply chain.
Market Impact: Limits 29% of smaller health system

Expanding Biomarker Diagnostic Infrastructure Sustains Demand

Continued expansion of biomarker diagnostic infrastructure, including cerebrospinal fluid testing and amyloid PET imaging capacity, across major developed and emerging markets is sustaining steady demand for both diagnostic testing and disease-modifying treatment eligible for biomarker-confirmed patients. Health systems report that expanded biomarker access can meaningfully improve early treatment initiation rates that far exceed the incremental cost of diagnostic infrastructure investment. This diagnostic infrastructure growth is expanding the addressable treatment market well beyond the developed markets that historically drove most category demand across the broader dementia care industry and adoption worldwide.
Market Impact: Adds 15% to diagnostic access delay

Market Restraints and Challenges

High Treatment Cost Limits Broad Patient Access

Anti-amyloid disease-modifying therapeutics carry substantially higher treatment costs than standard symptomatic management, and the root cause is that monoclonal antibody manufacturing, infusion administration, and mandatory MRI monitoring for safety surveillance require specialized infrastructure and ongoing clinical oversight that scale poorly for broad population-level treatment access. The commercial impact falls hardest on smaller health systems and rural memory care networks attempting to offer disease-modifying treatment, since treatment costs can represent a substantial share of total annual specialty pharmacy budget for a meaningful patient caseload. Manufacturers are mitigating this by offering outcomes-based pricing programmes and expanded payer coverage advocacy support.
Market Impact: Lifts biomarker pathway adoption by

Diagnostic Infrastructure Fragmentation Slows Treatment Access

Biomarker diagnostic infrastructure remains fragmented across different regions and healthcare systems, and the root cause is that amyloid PET imaging and cerebrospinal fluid testing capacity, while broadly expanding, retain meaningful geographic and specialist availability variations that complicate consistent treatment eligibility confirmation across every patient population simultaneously. The commercial impact falls hardest on patients in regions without established biomarker testing infrastructure, since limited diagnostic access increases both treatment delay and disease progression risk considerably before eligibility can be confirmed. Manufacturers are mitigating this by pursuing expanded diagnostic partnership networks that broaden testing access across underserved regions.
Market Impact: Lifts digital screening adoption by
4 additional market trends, 4 additional growth drivers, and 3 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Segmentation follows treatment and care type, the single dimension health systems specify against when structuring a dementia management procurement programme. Anti-amyloid therapeutics, digital cognitive monitoring, symptomatic therapeutics, diagnostic testing, behavioral symptom management, and care management services each serve a distinct clinical function, keeping treatment and care dimensions separate across every dementia care category served today.
dementia-management-market-market-share-analysis-1787305346937

Anti-Amyloid Disease-Modifying Therapeutics

Anti-amyloid disease-modifying therapeutics use monoclonal antibodies engineered to clear amyloid beta plaques from the brain, targeting the underlying disease pathology in early-stage patients rather than managing symptoms alone as legacy cholinesterase inhibitors do. Adoption is concentrated among specialty memory care centers and academic neurology practices with established biomarker diagnostic and infusion administration capability. Growth outpaces the broader market by roughly 1.86x as clinical evidence accumulates supporting earlier treatment intervention and biomarker testing infrastructure expands across major health systems. Manufacturers with proven diagnostic partnership networks and consistent infusion site training are capturing outsized share, since qualifying a new disease-modifying therapeutic requires extensive clinical infrastructure most health systems are reluctant to build without reason.
CAGR 17.5%

Digital Cognitive Assessment and Monitoring Platforms

Digital cognitive assessment and monitoring platforms use validated computerized testing and passive monitoring technology to detect early cognitive decline and track treatment response outside traditional in-person specialist evaluation settings. Adoption is concentrated among primary care networks and telehealth programmes seeking to expand early detection reach beyond limited specialty neurology capacity. Growth remains strong as validation evidence accumulates and primary care providers increasingly view digital screening as a meaningful driver of earlier referral and treatment initiation. Manufacturers completing expanded validation studies report meaningfully improved primary care adoption, reinforcing digital cognitive monitoring as a standard specification within early detection programmes across major healthcare networks and referral institutions nationwide and internationally today.
CAGR 13.2%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

North America retains the largest revenue base on dense specialty neurology infrastructure and established reimbursement pathways, while South Asia is compounding fastest as India's expanding aging population and healthcare infrastructure pull demand into the category nationwide across every major metropolitan referral hub today and beyond.

North America

United States health systems and specialty memory care networks, concentrated around major metropolitan academic medical centers, anchor the region's demand base as dense specialty neurology infrastructure and established reimbursement pathways drive proportional anti-amyloid and diagnostic demand across the care pathway. Canadian memory care networks continue steady treatment adoption tied to established provincial healthcare distribution systems covering major regional hospital centers. Broadening federal and private payer reimbursement for anti-amyloid therapeutics continues accelerating disease-modifying treatment adoption well ahead of many international peer markets facing less developed payment infrastructure. Growth trails East Asia because the region's aging population base is comparatively smaller relative to the expanding elderly cohorts driving growth elsewhere in the forecast.
Share: 32% | CAGR: 9.1% (2026 to 2036)

Western Europe

German and French health systems, operating under some of the world's most established public healthcare neurology coverage, sustain steady demand for both symptomatic and disease-modifying dementia therapeutics tied to national and European Union medical regulatory frameworks. United Kingdom memory care networks continue expanding biomarker diagnostic adoption tied to National Health Service capital investment programmes covering major regional and teaching hospital trusts. Regional pharmaceutical manufacturers maintain strong domestic penetration built on decades of neurology drug development expertise across the region. Regional growth trails East Asia and South Asia as the market's already high symptomatic treatment penetration limits the incremental upside further population aging alone can provide relative to less mature markets elsewhere in the forecast.
Share: 23% | CAGR: 7.9% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
dementia-management-market-country-cagr-analysis-1787305347463

Monetizing Diagnostic Partnerships and Care Coordination

Manufacturers are shifting commercial models toward biomarker diagnostic partnership subscriptions, infusion care coordination services, and multi-facility treatment protocol agreements rather than one-time prescription sales, since health system demand for demonstrated treatment eligibility now rivals raw drug pricing as a purchase criterion. This mirrors a broader shift across specialty pharmaceutical categories toward relationship-based commercial structures over transactional pricing.

Offering Biomarker Diagnostic Partnership Subscription Programs

Manufacturers are increasingly offering biomarker diagnostic partnership subscriptions that provide ongoing testing coordination, eligibility confirmation support, and payer documentation across a health system's full patient caseload, converting what was historically a one-time diagnostic referral into recurring annual revenue tied directly to a health system's treatment volume. Manufacturers report subscription attach rates above 43% among health systems managing the largest memory care caseloads, with renewal rates exceeding 85% once a health system experiences a full diagnostic cycle without a coverage denial. This diagnostic assurance increasingly determines vendor selection ahead of raw drug pricing during large health system contract negotiations.
Market Impact: Lifts recurring revenue share to ro

Bundling Infusion Care Coordination and Monitoring Services

Manufacturers are increasingly bundling infusion care coordination and safety monitoring services into treatment agreements, converting a previously fragmented clinical administration burden into predictable recurring revenue while reducing the risk of a health system facing an infusion capacity gap across a specific treatment site or patient population. Bundled coordination support typically reduces a health system's own clinical staffing workload meaningfully during treatment protocol expansion and safety reporting cycles. Manufacturers report coordination service attach rates rising fastest among health systems launching new infusion programmes for the first time, with roughly 32% of new agreements now including bundled coordination.
Market Impact: Cuts health system coordination wor

Offering Outcomes-Based Access and Pricing Programs

Manufacturers with disease-modifying therapeutic portfolios are increasingly offering outcomes-based pricing programmes that give smaller health systems a lower cost path to anti-amyloid treatment access without committing to full upfront treatment costs regardless of clinical results achieved. This outcomes-linked pricing path typically reduces a health system's financial risk exposure meaningfully compared with standard upfront purchase requirements, with outcomes-based programmes now supporting roughly 23% of total new disease-modifying treatments completed annually. Manufacturers report outcomes-based attach rates rising fastest among smaller health systems seeking treatment access without significant capital investment or committed budget.
Market Impact: Cuts adoption cost by roughly 31 pe

Structuring Multi-Facility Treatment Protocol Agreements Broadly

Manufacturers are increasingly structuring multi-year treatment protocol agreements that extend consistent diagnostic and treatment standards and pricing across a health system's entire regional network rather than negotiating each facility independently, giving health systems consistent treatment standards across every operating location served today and going forward. Health systems report cost of ownership reductions of roughly 18% once protocol standardization eliminates the redundant vendor management overhead multiple incompatible treatment standards previously required across the network. Manufacturers with proven multi-facility protocol agreement track records spanning dozens of locations are capturing outsized share of these agreements ahead of smaller competitors.
Market Impact: Cuts network-wide procurement cost

Who Controls the Margin Pool

The top five manufacturers hold roughly 52% combined share, a moderate to firm concentration reflecting both the substantial clinical trial and diagnostic partnership investment required for meaningful participation and the fragmented base of smaller regional producers serving local health system relationships. The gap between leading manufacturers and smaller regional producers is widening as large health systems restrict shortlists to companies with demonstrated diagnostic partnership depth an
Current competitive activity centers on three fronts: anti-amyloid therapeutic expansion targeting earlier-stage treatment eligibility, biomarker diagnostic partnership investment supporting broader testing access, and outcomes-based pricing programme development supporting smaller health system adoption. Several regional manufacturers are pursuing partnerships with established diagnostic imaging providers rather than building internal biomarker testing capability independently, a faster but margin-diluting route to participation.

Emerging pressure comes from Chinese and Indian manufacturers moving up the value chain from basic symptomatic treatment formats into certified disease-modifying and diagnostic systems sold initially to domestic health systems but increasingly targeting export markets as clinical evidence accumulates. Rankings among the top five could shift if a leader fails to close its diagnostic partnership or treatment outcomes gap, since health systems increasingly evaluate evidence depth ahead of price during large contract decisions.
dementia-management-market-company-positioning-matrix-1787305347981

Competitive Moat and Risk Dimensions

EISAI CO LTD

Moat: Deep biomarker partnership network

Eisai's decades of accumulated biomarker diagnostic partnership relationships and early-mover anti-amyloid clinical evidence give it durable credibility among health systems who weigh proven treatment eligibility confirmation heavily, since qualifying a new disease-modifying vendor without comparable diagnostic partnership history carries meaningful clinical and reimbursement risk. That credibility compounds with every additional health system Eisai brings into its network.
EISAI CO LTD

Risk: Slower niche regional response

Eisai's scale and broad clinical trial footprint can slow its response to niche regional diagnostic partnership requests that smaller specialized manufacturers serve more quickly, occasionally costing it accounts among health systems prioritizing rapid custom support over comprehensive global network convenience. That responsiveness gap is unlikely to close soon.
BIOGEN INC

Moat: Integrated therapeutic and diagnostic portfolio

Biogen's combination of anti-amyloid therapeutic manufacturing and diagnostic partnership infrastructure under a single health system relationship gives it a design-in advantage with hospitals seeking one accountable vendor rather than piecemeal sourcing across multiple specialized suppliers. That portfolio advantage compounds with every additional health system Biogen brings online.
BIOGEN INC

Risk: Premium pricing limits smaller reach

Biogen's premium therapeutic pricing structure can limit its reach among smaller, budget-constrained health systems that prioritize lower cost symptomatic formats over disease-modifying treatment capability, occasionally ceding entry-tier accounts to lower-cost regional competitors focused on price-sensitive procurement segments. That gap is unlikely to close without a lower-cost treatment tier introduction.

Players Tracked

Prominent Players

Eisai Co Ltd
Biogen Inc
Eli Lilly and Company
Novartis AG
Otsuka Holdings Co Ltd

Other Key Players

Roche Holding AG
AC Immune SA
Alector Inc
Cassava Sciences Inc
Cognition Therapeutics Inc
Athira Pharma Inc
Anavex Life Sciences Corp
Prothena Corporation plc
Vaxxinity Inc
INmune Bio Inc
Denali Therapeutics Inc
Cerevel Therapeutics Holdings Inc
Acumen Pharmaceuticals Inc
Alzheon Inc
Annovis Bio Inc

Recent Developments

AUGUST 2025

Eisai Commissions New Biomarker Diagnostic Partnership Network

Eisai commissioned a new dedicated biomarker diagnostic partnership network, adding meaningful testing capacity to address surging demand from health systems requiring rapid treatment eligibility confirmation across their expanding memory care programmes. The expansion targets both existing health system relationships and new academic partnerships launching next year.
Signal: Confirms biomarker diagnostic capacity exp
NOVEMBER 2025

Biogen Signs Multi-Facility Treatment Protocol Agreement

Biogen signed a multi-year treatment protocol standardization agreement with a major regional health system, covering consistent diagnostic and treatment standards and direct support across dozens of affiliated memory care facilities nationwide. The agreement is a supply arrangement rather than a joint venture or acquisition, extending Biogen's multi-facility presence considerably.
Signal: Highlights protocol standardization bundli
FEBRUARY 2026

Eli Lilly Acquires Regional Cognitive Monitoring Software Provider

Eli Lilly completed the acquisition of a regional cognitive monitoring software provider, strengthening its digital screening capability and expanding its ability to support health systems navigating early detection and treatment eligibility requirements across every major market. The deal reinforces Eli Lilly's positioning across the broader dementia management market worldwide.
Signal: Signals continued consolidation of special

Monoclonal Antibody and Diagnostic Cost Exposure

Monoclonal antibody biomanufacturing, specialty cell culture media, and diagnostic imaging and testing infrastructure together represent an estimated 42 to 52% of dementia therapeutic cost of goods sold across most manufacturers. Monoclonal antibody manufacturing capacity remains concentrated among a small number of qualified biologics production facilities, creating a narrower supply base than most broader pharmaceutical categories rely upon for comparable production inputs.
Biologics manufacturing and specialty raw material price volatility during 2021 and 2022 significantly raised dementia therapeutic manufacturing costs broadly, and several manufacturers flagged the disruption in annual reports as a persistent cost pressure affecting multiple biologics categories simultaneously across the sector. Several manufacturers disclosed that biomanufacturing capacity lead times stretched beyond twenty weeks during the tightest period, forcing some smaller producers to delay shipments or substitute costlier secondary market capacity to maintain existing health system supply commitments.

Smaller regional manufacturers carry disproportionate exposure to these input swings since they lack the purchasing scale to negotiate multi-year fixed pricing directly with biomanufacturing suppliers that the top five manufacturers secure more easily through established relationships. This gap is widest for producers dependent entirely on merchant manufacturing capacity, leaving them more vulnerable to margin compression during capacity spikes across the category.
dementia-management-market-cost-volatility-analysis-1787305348178

Long-Term Biomanufacturing Capacity Contracts

Leading manufacturers now lock multi-year capacity directly with biologics manufacturing facilities serving their primary production needs, avoiding the spot market cost volatility that stretched capacity lead times beyond twenty weeks during the 2021 to 2022 shortage and protecting production schedules against health system supply disruption across major markets worldwide throughout sustained periods of capacity constraint affecting the wider industry.

Vertical Integration Into Biomanufacturing Capacity

Top five manufacturers increasingly build internal biologics manufacturing capacity rather than relying entirely on third-party contract manufacturers, smoothing production timelines and insulating supply from the capacity sourcing volatility smaller regional manufacturers remain exposed to directly, a practice that has become standard procurement policy since disease-modifying demand accelerated considerably across the industry and among smaller producers.

Diversified Manufacturing Sourcing Across Multiple Facilities

Manufacturers without full vertical integration are increasingly qualifying multiple biomanufacturing facilities across different geographic regions, reducing exposure to any single facility's capacity constraints or production disruptions and giving manufacturers greater negotiating leverage during periodic capacity pricing renewal discussions across the broader supply chain network spanning multiple continents, regulatory jurisdictions, and currency zones worldwide.

Portfolio Architecture for Margin Defence

Portfolio architecture splits across three tiers: entry priced standard symptomatic therapeutics competing largely on cost, certified diagnostic testing and biomarker confirmation services carrying clinical evidence value that commands a durable price premium, and next generation anti-amyloid disease-modifying therapeutics bundled with diagnostic partnership and care coordination services. Gross margins widen moving up this ladder as clinical evidence and biomanufacturing barriers concentrate ha
The volume versus premium tension is sharpest in standard symptomatic therapeutics, where regional competition has compressed prices fastest, pushing established manufacturers to defend share through diagnostic and coordination bundling rather than matching commodity pricing directly on drug cost alone. Anti-amyloid disease-modifying therapeutics retain the strongest pricing power because clinical evidence investment and multi-year diagnostic partnership relationships discourage health systems from switching vendors mid-treatment, a dynamic strengthening as adoption broadens.

High value margin pools concentrate in anti-amyloid disease-modifying therapeutics paired with continuous diagnostic partnership and care coordination service contracts, where recurring revenue and high switching costs together support gross margins well above the portfolio average. Manufacturers are prioritizing capital toward this tier even though it remains a minority of total treatment volume shipped across the broader portfolio today, betting the mix shifts decisively within the decade ahead.

Volume / Commodity-Adjacent Tier

Basic standard symptomatic therapeutics competing primarily on unit price against regional producers, with limited service attach and thin per-unit margins across most transactions and smaller health system accounts nationwide.
Gross Margin: 18-26%

Premium / Certified Tier

Diagnostic testing and biomarker confirmation services serving complex early-stage evaluation applications, where clinical evidence depth and testing accuracy support durable pricing across the industry and every managed patient account.
Gross Margin: 32-40%

Sustainability / Regulatory / Next-Generation Tier

Anti-amyloid disease-modifying therapeutics bundled with diagnostic partnership, care coordination, and monitoring service contracts, sold on recurring clinical assurance value rather than drug pricing alone, increasingly the default specification across networks.
Gross Margin: 44-52%
dementia-management-market-portfolio-architecture-1787305348678

Diagnostic Contracts Anchor Recurring Treatment Revenue

Dementia management economics function increasingly like an annuity once a diagnostic partnership relationship is established, since biomarker testing subscriptions, care coordination services, and periodic treatment monitoring generate recurring revenue for years after the initial treatment agreement closes. This recurring layer now represents a growing share of total category revenue and is the primary reason manufacturers compete aggressively on initial health system placement even at thin en
Adoption depth varies sharply by end use vertical. Large academic memory care centers run near saturated biomarker diagnostic coverage and generate mostly renewal and coordination demand, while smaller regional and community health systems are still building out first time diagnostic pathway coverage, generating a different mix of new installation revenue layered on the maturing replacement base.

Buyer profiles are shifting generationally as newer neurologists who trained primarily on biomarker-confirmed and disease-modifying treatment frameworks increasingly influence procurement decisions alongside veteran clinicians who remember when dementia management was a purely symptomatic and supportive care specialty. This is accelerating demand for manufacturers with strong diagnostic and coordination capability even among health system buyers who historically evaluated dementia treatment purely on unit cost and prescriber familiarity alone.
dementia-management-market-end-use-penetration-index-1787305349169

Where Dementia Treatment Strategy Should Focus

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / DIAGNOSTIC PARTNERSHIP INVESTMENT

Prioritize biomarker confirmation depth over marginal pricing

Unit pricing has become a secondary consideration across most large health system procurement decisions, no longer the primary differentiator given rising treatment eligibility scrutiny across every major healthcare jurisdiction. Health systems now evaluate biomarker diagnostic depth and treatment outcomes evidence ahead of marginal price savings that once justified switching vendors on their own. Manufacturers that continue competing primarily on standard drug pricing risk losing share to diagnostic-focused rivals bundling testing, coordination, and monitoring into a single recurring relationship that is harder to unwind once established.
02 / SERVICE MONETIZATION STRATEGY

Shift commercial models toward diagnostic and coordination revenue

Standard therapeutic margins will keep compressing as regional manufacturers gain share at the entry tier of the category across most emerging markets. Manufacturers that convert biomarker diagnostics, care coordination, and outcomes-based pricing into contracted recurring revenue will outperform peers still pricing primarily around one-time prescription sales alone. This shift also raises health system switching costs meaningfully, since replacing a disease-modifying vendor requires displacing an entrenched, multi-year diagnostic and coordination relationship built over years of accumulated clinical staff trust across every managed facility.
03 / REGIONAL GROWTH PRIORITIZATION

Weight investment toward South Asia and East Asia over mature markets

South Asia and East Asia are compounding faster than Western Europe on both share and CAGR, driven by expanding aging population volume, rising healthcare infrastructure investment, and first time diagnostic and treatment access across previously underserved regional health system networks. Manufacturers weighting manufacturing and diagnostic investment toward these regions ahead of competitors will capture a disproportionate share of new treatment volume revenue. Mature markets, running mostly on established prescribing bases, simply cannot replicate that category of growth at comparable scale or rate over the coming decade of forecast activity.
04 / HEALTH SYSTEM ACCESS

Expand outcomes-based pricing programmes ahead of demand

The gap between rising treatment eligibility scrutiny and available disease-modifying access at smaller health systems represents a substantial growth opportunity that most manufacturers are not yet equipped to capture efficiently given the specialized diagnostic and coordination infrastructure required. Manufacturers that invest early in dedicated outcomes-based programmes will be better positioned to capture accounts without the extended financial justification timelines currently limiting some competitors. Manufacturers ignoring this opportunity risk ceding smaller health system revenue to competitors who have already solved the access problem.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Dementia Management Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Dementia Management Exposure Evaluation 2025-26
CLIENT PROFILE
The client operates a multi-hospital regional health system covering several major metropolitan and suburban markets, managing several thousand dementia cases annually across affiliated memory care clinics and referral partnerships nationwide (client-reported, unverified by MMA). Its existing treatment approach relied primarily on standard symptomatic therapeutics across most facilities, with limited biomarker diagnostic experience among its clinical staff.
STRATEGIC CHALLENGE
Facing rising patient demand for disease-modifying treatment and increasing payer scrutiny of treatment eligibility documentation, health system leadership sought to systematically expand biomarker diagnostic and anti-amyloid treatment capability across all affiliated memory care clinics within eighteen months, while managing infusion infrastructure and building clinical staff confidence with the newer treatment modality and workflow.
MMA APPROACH
MMA benchmarked five candidate diagnostic and therapeutic suppliers against clinical outcomes evidence, diagnostic partnership depth, and total cost of ownership over a five year horizon, then modeled rollout sequencing to prioritize the highest-volume memory care clinics first during the phased expansion programme currently under review by clinical and administrative leadership teams across the network.
KEY FINDINGS
  1. Three of five candidate suppliers evaluated could not confirm dedicated biomarker diagnostic partnership capacity within the client's required programme timeline window at all.
  2. Standardized diagnostic and treatment procurement reduced projected annual eligibility confirmation delays by 34% versus continued fragmented referral reliance across comparable case volumes, based on modeling completed during evaluation (client-reported, unverified by MMA).
  3. Centralizing outcomes data reporting was projected to cut compliance administrative workload meaningfully across the client's regional memory care network, according to internal operations modeling completed by the client.
  4. Memory care clinics facing the highest early-stage diagnosis volume carried the highest near term rollout priority, reprioritizing the client's original sequencing considerably ahead of the initial eighteen month plan.
CLIENT PROFILE
The client operates a multi-hospital regional health system covering several major metropolitan and suburban markets, managing several thousand dementia cases annually across affiliated memory care clinics and referral partnerships nationwide (client-reported, unverified by MMA). Its existing treatment approach relied primarily on standard symptomatic therapeutics across most facilities, with limited biomarker diagnostic experience among its clinical staff.
STRATEGIC CHALLENGE
Facing rising patient demand for disease-modifying treatment and increasing payer scrutiny of treatment eligibility documentation, health system leadership sought to systematically expand biomarker diagnostic and anti-amyloid treatment capability across all affiliated memory care clinics within eighteen months, while managing infusion infrastructure and building clinical staff confidence with the newer treatment modality and workflow.
MMA APPROACH
MMA benchmarked five candidate diagnostic and therapeutic suppliers against clinical outcomes evidence, diagnostic partnership depth, and total cost of ownership over a five year horizon, then modeled rollout sequencing to prioritize the highest-volume memory care clinics first during the phased expansion programme currently under review by clinical and administrative leadership teams across the network.
KEY FINDINGS
  1. Three of five candidate suppliers evaluated could not confirm dedicated biomarker diagnostic partnership capacity within the client's required programme timeline window at all.
  2. Standardized diagnostic and treatment procurement reduced projected annual eligibility confirmation delays by 34% versus continued fragmented referral reliance across comparable case volumes, based on modeling completed during evaluation (client-reported, unverified by MMA).
  3. Centralizing outcomes data reporting was projected to cut compliance administrative workload meaningfully across the client's regional memory care network, according to internal operations modeling completed by the client.
  4. Memory care clinics facing the highest early-stage diagnosis volume carried the highest near term rollout priority, reprioritizing the client's original sequencing considerably ahead of the initial eighteen month plan.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (Months 1-6): Complete supplier evaluation and diagnostic capacity reservation for the three highest-scoring candidates identified through careful independent review. Phase 2: Phase 2 (Months 7-14): Execute clinical staff training and treatment coordination across the highest volume memory care clinics first nationwide and regionally. Phase 3: Phase 3 (Months 15-18): Complete network-wide rollout and finalize centralized outcomes tracking dashboard fully enabled for clinical leadership review and sign-off.
OUTCOME
The health system completed disease-modifying treatment rollout across all priority memory care clinics within the eighteen month window and reported meaningfully improved diagnostic eligibility confirmation during subsequent internal reviews (client-reported, unverified by MMA). System leadership gained centralized treatment visibility previously unavailable across its distributed regional memory care network.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Dementia Management Market?

The global dementia management market reached an estimated $9.2 billion in 2025. Growth is driven by rising dementia prevalence and expanding anti-amyloid treatment adoption worldwide.

How large will the Dementia Management Market be by 2036?

The market is projected to reach approximately $24.7 billion by 2036, roughly 2.46 times its 2026 value. Anti-amyloid disease-modifying therapeutics drive most of the added value across the category.

What is the CAGR for the Dementia Management Market 2026 to 2036?

The base case CAGR is 9.4% through 2036. Bull and bear scenarios range from roughly 8.1% to 10.6%, depending on biomarker diagnostic expansion pace and treatment adoption speed.

Which segment is growing fastest?

Anti-amyloid disease-modifying therapeutics lead at a 17.5% CAGR, about 1.86x the overall market rate. Growth is concentrated among specialty memory care centers with established diagnostic capability.

Who are the major companies in the Dementia Management Market?

Eisai, Biogen, Eli Lilly, Novartis, and Otsuka lead the category. Combined, the top five suppliers hold roughly 52% of global revenue on a consistent basis.

Which country is growing fastest?

China leads country level growth at an estimated 15.2% CAGR. Expanding aging population and healthcare infrastructure are driving treatment demand across the region's healthcare base.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Treatment and Care Type

  • Anti-Amyloid Disease-Modifying Therapeutics
  • Digital Cognitive Assessment and Monitoring Platforms
  • Cholinesterase Inhibitor and Memantine Therapeutics
  • Dementia Diagnostic Imaging and Biomarker Testing
  • Behavioral and Psychological Symptom Management Products
  • Institutional and Home-Based Care Management Services

By End-Use Healthcare Setting

  • Academic and Specialty Memory Care Centers
  • Community and Regional Hospitals
  • Long-Term Care and Nursing Facilities
  • Home Care and Telehealth Settings

By Commercial Dimension

  • Direct Manufacturer Supply Agreements
  • Group Purchasing Organization Contracts
  • Outcomes-Based Pricing Programs
  • Diagnostic Partnership Service Contracts

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The dementia management market covers therapeutics, diagnostic testing, and care management services used to treat and manage Alzheimer's disease and related dementias, spanning anti-amyloid disease-modifying drugs, cholinesterase inhibitors and memantine, diagnostic imaging and biomarker testing, behavioral symptom management products, and institutional and home-based care management services. General neurological disorder treatments are excluded from market scope.
Quantitative Units
USD billions (current prices); treated patient episodes where disclosed
Segmentation Dimensions
By Treatment and Care Type; By End-Use Healthcare Setting; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, China, Germany, France, UK, Japan, South Korea, India, Australia, Canada, Brazil, Mexico, Thailand, Malaysia, Indonesia, Vietnam, UAE, Saudi Arabia, South Africa, Nigeria, Turkey, Poland, Netherlands, Italy, Spain, Sweden, Switzerland, Argentina, Colombia, Singapore, and additional markets relevant to this sector
Key Companies Profiled
Eisai Co Ltd, Biogen Inc, Eli Lilly and Company, Novartis AG, Otsuka Holdings Co Ltd, Roche Holding AG, AC Immune SA, Alector Inc, Cassava Sciences Inc, Cognition Therapeutics Inc, Athira Pharma Inc, Anavex Life Sciences Corp, Prothena Corporation plc, Vaxxinity Inc, INmune Bio Inc, Denali Therapeutics Inc, Cerevel Therapeutics Holdings Inc, Acumen Pharmaceuticals Inc, Alzheon Inc, Annovis Bio Inc
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-HLT-154
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Dementia Management Market Report (2026 to 2036).

The full report delivers a complete quantitative and qualitative assessment of the global dementia management market through 2036. It includes detailed segmentation by treatment and care type, healthcare setting, and commercial channel, alongside country level sizing across thirty markets covering every major treatment demand center. Competitive profiles cover twenty companies with diagnostic partnership depth, treatment outcomes evidence, and distribution benchmarking assessed on a consistent revenue basis. Buyers also receive access to the underlying primary survey and expert interview datasets referenced throughout the analysis, along with editable data tables.
Segment level CAGR and sizing tables
Regional and country level market breakdowns
Twenty company competitive profiles and benchmarks
Detailed biomarker diagnostic capacity benchmarking matrix
Input cost and supply chain risk analysis
Primary survey and expert interview datasets completely included

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts